Coherus Oncology (CHRS) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Coherus Oncology (CHRS) over the past year, gaining 50.0% versus a loss of 40.9%. Over five years, NERV leads with a -69.7% price change compared with -94.1% for CHRS. Minerva Neurosciences is the larger company by market cap ($154.2 million vs $152.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | NERV |
|---|---|---|
| Share price | $0.9891 | $3.23 |
| Market cap | $152.82M | $154.22M |
| 1-day change | -2.07% | -1.22% |
| YTD return | -28.87% | -18.66% |
| 1-year return | -40.94% | +50.00% |
| 5-year return | -94.06% | -69.72% |
| EPS (TTM) | $-1.25 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $12.46 |
| 52-week low | $0.9801 | $2.24 |
| Distance from 52-week high | -62.19% | -74.08% |
| Analyst consensus | none | none |
| Avg. price target upside | +683.54% | +219.81% |
| Average volume | 1.15M | 184.44K |
| Shares outstanding | 154.50M | 47.75M |
| Employees | 144 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed CHRS by 90.9 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
CHRS vs NERV FAQ
Which is bigger, Coherus Oncology or Minerva Neurosciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $154.22M compared with $152.82M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or NERV?
NERV returned +50.00% over the past 12 months, compared with -40.94% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Minerva Neurosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Coherus Oncology and Biotechnology: Pharmaceutical Preparations for Minerva Neurosciences.